This article directly stems from the research process for our global venture capital investors database. Based on this list and our advanced keyword crawler technology, we created a list of venture capital investors that mention oncology-related keywords on their website. The list – offered as an Excel file – is perfectly suited to get in touch with the most relevant investors in the field.
This article highlights three significant oncology venture capital investment funds in Asia from our keyword crawler generated oncology VC investor list.
1. Viva Ventures Biotech Fund (Hong Kong)
Viva Ventures is a venture capital investment firm, that supports discovery-stage start-ups focusing on biotech. They stand out with extensive expertise and industry know-how for early-stage funding. The company represents a diverse portfolio, including metabolic diseases, vascular diseases and cancer. One company targeting the need for oncology related research is Project F1, who develop pharmaceuticals for acute lymphoblastic leukaemia. Another portfolio company is Sisu, who is researching a drug for prostate cancer.
2. Atinum Investment (Seoul)
Atinum Investment is a South Korean VC investor who fund start-ups in the growth stage that focus on driving market and technology innovations. The company is interested in IT, biotech and healthcare start-ups and have invested in 425 companies. An oncology focused company, Atinum Investment has invested in, is Curocell. Curocell is developing a CAR-T therapy, a cancer immunotherapy, for non-responding patients.
3. Pix Vine Capital (Singapore)
Pix Vine Capital was founded in 2007 and invests in early-stage businesses in infotech, medtech, and fintech. They follow a high risk – high return philosophy and have invested in over 40 ventures in different countries, including Israel, China, India, Vietnam, Singapore, and many more. One of them is Qritive, an AI-powered cancer diagnosis solution that helps doctors analyse microscopic images and text data from patients. This can impact cancer care at all levels by enabling higher accuracy, lower costs and improved outcomes.
Picture Source: Pawel Czerwinski